Search Results

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India.

Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that it has entered into a license agreement with Sun Pharmaceutical Industries Limited to commercialise a first-in-class innovative drug, Tyvalzi™ in India.

Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that The Directorate General of Health Services, India on May 31st, 2023, granted the manufacture and marketing of Sovateltide Injection for cerebral ischemic stroke patients.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two key publications.

Pharmazz, Inc. (“Pharmazz” or the “Company”) announced that the US Food and Drug Administration (FDA) has issued a proceed forward letter regarding the Company’s Investigational New Drug (“IND”) application that includes the protocol entitled, “A Multicentric, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Study To Assess The Safety And Efficacy Of Sovateltide In Patients With Acute Cerebral Ischemic Stroke.”

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.

Pharmazz, Inc. announced two presentations on sovateltide as a treatment for acute ischemic stroke at the 14th World Stroke Congress October 26-29, 2022, in Singapore.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced today positive topline results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.